eGFRcr-cys Levels More Strongly Linked to Adverse Outcomes in Seniors
By Elana Gotkine HealthDay Reporter
MONDAY, Jan. 29, 2024 -- In older patients, a low estimated glomerular filtration rate (eGFR) based on creatinine and cystatin C levels (eGFRcr-cys) is more strongly associated with adverse outcomes compared with low eGFR based on creatinine level (eGFRcr), according to a study published online Jan. 30 in the Annals of Internal Medicine.
Edouard L. Fu, Ph.D., from the Karolinska Institute in Stockholm, and colleagues note that the commonly accepted threshold of GFR to define chronic kidney disease (CKD) is <60 mL/min/1.73 m2 and is based partly on the associations between eGFR and the frequency of adverse events, which are weaker in older adults. The authors assessed associations between eGFRcr versus eGFRcr-cys and eight outcomes in older adults. Data were included for 82,154 participants aged 65 years and older with outpatient creatinine and cystatin C testing.
The researchers observed monotonic associations between eGFRcr-cys and outcomes, while most associations for eGFRcr were U-shaped. Compared with eGFRcr, eGFRcr-cys was more strongly associated with outcomes. The adjusted hazard ratios (95 percent confidence intervals) for all-cause mortality were 1.2 (1.1 to 1.3) and 1.0 (0.9 to 1.0) for eGFRcr-cys and eGFRcr, respectively, for 60 versus 80 mL/min/1.73 m2, and 2.6 (1.2 to 5.8) and 1.4 (0.7 to 2.8), respectively, for kidney failure with replacement therapy. In subgroups, including those with a urinary albumin-creatinine ratio below 30 mg/g, the findings were similar.
"The broad range of risks associated with CKD at older age is better appreciated when cystatin C is included in GFR estimation," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
SGLT2 Inhibitors Improve Outcomes in Patients With Diabetes Plus Kidney Disease
THURSDAY, May 2, 2024 -- Use of sodium–glucose cotransporter-2 inhibitors (SGLT2is) is associated with a substantially lower risk for dialysis and cardiovascular disease in...
Leukocyte Glucose Index, Arteriovenous Fistula Failure Linked in ESKD
MONDAY, April 22, 2024 -- For patients with end-stage kidney disease (ESKD), a high preoperative leukocyte glucose index (LGI) is associated with arteriovenous fistula (AVF)...
Risk Prediction Model Accurate for Chronic Kidney Disease
FRIDAY, April 19, 2024 -- For individuals with moderate-to-severe chronic kidney disease (CKD), a model, KDpredict, can accurately predict the risk for kidney failure and death...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.